A multicenter randomized study evaluating the efficacy and safety of HMG-CoA reductase inhibitors (statins) in dyslipidemic patients with nephrosclerosis.

Trial Profile

A multicenter randomized study evaluating the efficacy and safety of HMG-CoA reductase inhibitors (statins) in dyslipidemic patients with nephrosclerosis.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 May 2016

At a glance

  • Drugs Pitavastatin (Primary)
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Acronyms LAKE
  • Most Recent Events

    • 24 Jul 2012 Official title amended as reported by University Hospital Medical Information Network - Japan.
    • 27 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top